JPH05186769A - Antioxidant which eliminates active oxygen - Google Patents
Antioxidant which eliminates active oxygenInfo
- Publication number
- JPH05186769A JPH05186769A JP2160692A JP2160692A JPH05186769A JP H05186769 A JPH05186769 A JP H05186769A JP 2160692 A JP2160692 A JP 2160692A JP 2160692 A JP2160692 A JP 2160692A JP H05186769 A JPH05186769 A JP H05186769A
- Authority
- JP
- Japan
- Prior art keywords
- antioxidant
- active oxygen
- galloyl
- glucose
- tannin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、加水分解型タンニンを
有効成分とする活性酸素消去作用を有する抗酸化剤に関
するものである。更に詳細には、本発明は、加水分解型
タンニンの内でも特に効果が高い1,2,6−トリ−O
−ガロイル−β−D−グルコースおよび/または2,3
−ジ−O−ガロイル−4,6−(O−4,4’,5,
5’,6,6’−ヘキサヒドロキシジフェノイル)−D
−グルコースを主成分とする抗酸化剤に関するものであ
り、食品産業、医薬品産業、化粧品産業などに応用され
るものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an antioxidant having a hydrolyzable tannin as an active ingredient and having an active oxygen scavenging action. More specifically, the present invention is 1,2,6-tri-O, which is particularly effective among hydrolyzed tannins.
-Galloyl-β-D-glucose and / or 2,3
-Di-O-galloyl-4,6- (O-4,4 ', 5,
5 ', 6,6'-hexahydroxydiphenoyl) -D
-It relates to an antioxidant containing glucose as a main component, and is applied to the food industry, the pharmaceutical industry, the cosmetic industry, and the like.
【0002】[0002]
【従来の技術】タンニンは一般に植物起源のポリフェノ
ール類を指し、天然有機化合物として広く分布してい
る。このタンニンは鞣皮料、染料、紙、布、糸等の補
強、防水剤として種々の用途がある。またタンニンのも
つ収斂性を利用した収斂止瀉剤、整腸剤等の医薬品とし
ての使用も行なわれている。BACKGROUND OF THE INVENTION Tannin generally refers to polyphenols of plant origin and is widely distributed as a natural organic compound. This tannin has various uses as a tanning material, dye, paper, cloth, thread, etc. reinforcement and waterproofing agent. In addition, it is also used as a medicine such as an anti-astringent agent and an intestinal regulating agent which utilize the astringent property of tannin.
【0003】近時、タンニンの還元および酸化防止作用
から、タンニンが生体内の脂質過酸化反応を防止する作
用を想定し、生体内の過酸化反応であるアラキドン酸代
謝および肝ミクロソーム、ミトコンドリアでの過酸化脂
質生成反応を中心に研究し、ゲンノショウコに含まれる
各エキスおよびゲンノショウコの主タンニンであるゲラ
ニインを過酸化脂質を投与したラットに投与して、血清
のGOT、GPTおよび過酸化脂質の上昇が抑制され、
加水分解型タンニンが縮合型タンニンより有効であった
との報告がある(ケミカル アンド ファーマシューテ
ィカル ブレチン(Chem.Pharm.Bul
l.)31,1625,(1983);32,1866
(1984))。Recently, it has been assumed that tannin prevents lipid peroxidation in vivo from the action of reducing and antioxidant tannin. Metabolism of arachidonic acid, which is a peroxidation reaction in vivo, and liver microsomes and mitochondria Studies were conducted focusing on the lipid peroxide production reaction, and each of the extracts contained in ginkgo biloba and geraniin, which is the main tannin of ginkgo biloba, was administered to rats treated with lipid peroxide to increase serum GOT, GPT and lipid peroxide. Suppressed,
It was reported that the hydrolyzed tannin was more effective than the condensed tannin (Chem. Pharm.
l. ) 31, 1625, (1983); 32, 1866.
(1984)).
【0004】生体内においてキサンチン(XA)−キサ
ンチンオキシデース(XOD)系で発生するスーパーオ
キサイドアニオンラジカルを始めとする活性酸素種が炎
症、白内障、動脈硬化、心筋虚血、老化、痙攣、脳卒
中、糖尿病などに関与することが知られている。また生
体内に存在して活性酸素消去作用を有する酵素であるス
ーパーオキサイドディスミューテース(SOD)がスー
パーオキサイドアニオンラジカルを不活性化し、生体内
で起こるラジカル反応に起因する諸疾患を予防する役割
を演じている。Reactive oxygen species including superoxide anion radicals generated in the xanthine (XA) -xanthine oxidase (XOD) system in vivo are inflammation, cataract, arteriosclerosis, myocardial ischemia, aging, convulsion, stroke, It is known to be involved in diabetes and the like. In addition, superoxide dismutase (SOD), which is an enzyme that exists in the body and has an active oxygen scavenging action, inactivates superoxide anion radicals and plays a role in preventing various diseases caused by radical reactions occurring in the body. Acting.
【0005】生体内の代謝により発生する活性酸素に起
因する炎症、発癌、放射能障害、免疫、白内障、動脈硬
化、心筋虚血、老化、痙攣、脳卒中、糖尿病などの諸疾
患の予防、治療に効果のある薬剤としてスーパーオキサ
イドディスミューテース(SOD)を用いて生体内活性
酸素に由来する障害の予防および治療剤も知られている
(特開昭56−32422号公報)。For the prevention and treatment of various diseases such as inflammation, carcinogenesis, radiation damage, immunity, cataract, arteriosclerosis, myocardial ischemia, aging, convulsion, stroke, diabetes caused by active oxygen generated by metabolism in the living body. A prophylactic and therapeutic agent for a disorder derived from in vivo active oxygen using superoxide dismutase (SOD) as an effective agent is also known (JP-A-56-32422).
【0006】またビタミンE、ビタミンCが活性酸素を
消去する物質として上記の諸疾患の予防と治療に使用さ
れている。Vitamin E and vitamin C are used as substances for eliminating active oxygen in the prevention and treatment of the above-mentioned diseases.
【0007】[0007]
【発明が解決しようとする問題点】前記した従来技術に
おいて、スーパーオキサイドディスミューテース(SO
D)は酵素蛋白質であるために高純度に製造の収率を高
くできないこと、生体内に投与した時の血中濃度の維持
が困難であることなどの欠点を持っている。一方、ビタ
ミンE、ビタミンCは生体内における活性酸素消去の作
用は十分でないなどの難点があり、さらに強力な作用を
有しかつ入手に制限のない低分子量の活性酸素消去剤
(SOD様作用低分子物質)、しかも、スーパーオキサ
イドのみならず、過酸化水素、ヒドロキシラジカル、一
重項酸素といった各種の活性酸素の消去にも広範に使用
可能な、汎用性の高い活性酸素消去剤が、業界において
強く要望されている。DISCLOSURE OF THE INVENTION Problems to be Solved by the Invention In the above-mentioned prior art, the superoxide dismutase (SO
Since D) is an enzyme protein, it has drawbacks such that the production yield cannot be increased to a high degree of purity and it is difficult to maintain the blood concentration when administered in vivo. On the other hand, vitamin E and vitamin C have drawbacks such as insufficient action of scavenging active oxygen in the living body, and further have strong action and availability of low molecular weight active oxygen scavenger (low SOD-like action). In addition to superoxide, a highly versatile active oxygen scavenger that can be widely used to eliminate not only superoxide but also various active oxygen such as hydrogen peroxide, hydroxy radicals, and singlet oxygen Is requested.
【0008】[0008]
【問題点を解決するための手段】本発明者らは活性酸素
を強力に消去する物質を得る目的で研究を進めた結果、
ユーカリから分離した加水分解型タンニンである1,
2,6−トリ−O−ガロイル−β−D−グルコース及び
2,3−ジ−O−ガロイル−4,6−(O−4,4’,
5,5’,6,6’−ヘキサヒドロキシジフェノイル)
−D−グルコースが生体内で生成する活性酸素を強力に
消去し、しかも従来の抗酸化性を有する物質であるビタ
ミンE、ビタミンCでは十分消去されなかった生体内で
悪玉と考えられるスーパーオキサイドアニオンラジカル
を強力に消去することを見いだし、本発明を完成した。
本発明はかかる研究をもって完成された加水分解型タン
ニンを有効成分とする活性酸素消去作用を有する抗酸化
剤に関するものである。[Means for Solving the Problems] As a result of the research conducted by the present inventors for the purpose of obtaining a substance that strongly eliminates active oxygen,
1, which is a hydrolyzable tannin isolated from eucalyptus
2,6-tri-O-galloyl-β-D-glucose and 2,3-di-O-galloyl-4,6- (O-4,4 ′,
5,5 ', 6,6'-hexahydroxydiphenoyl)
-D-Glucose strongly eliminates the active oxygen generated in the body, and superoxide anion, which is considered to be a bad body in the body, was not sufficiently eliminated by the conventional antioxidant substances Vitamin E and Vitamin C. The inventors have found that radicals are strongly eliminated, and have completed the present invention.
The present invention relates to an antioxidant having an active oxygen scavenging action, which has hydrolyzed tannin as an active ingredient, completed by such research.
【0009】本発明においては、加水分解型タンニンで
あればすべてのものが使用できるが、例えば、1,2,
6−トリ−O−ガロイル−β−D−グルコース及び2,
3−ジ−O−ガロイル−4,6−(O−4,4’,5,
5’,6,6’−ヘキサヒドロキシジフェノイル)−D
−グルコースが好適である。なお、これらの物質は公知
である{ケミカル アンド ファーマシューティカル
ブレチン(Chem.Pharm. Bull.)2
9,2862(1981)、ファイトケミストリー(P
hytochemistry)15,211(197
6)}。しかしながら、活性酸素を消去する生理作用に
ついては本発明をもって最初とされる。In the present invention, any hydrolyzable tannin can be used. For example, 1, 2,
6-tri-O-galloyl-β-D-glucose and 2,
3-di-O-galloyl-4,6- (O-4,4 ', 5
5 ', 6,6'-hexahydroxydiphenoyl) -D
-Glucose is preferred. These substances are known {Chemical and Pharmaceuticals.
Bulletin (Chem. Pharm. Bull.) 2
9, 2862 (1981), Fight Chemistry (P
hytochemistry 15, 211 (197)
6)}. However, the physiological action of eliminating active oxygen is the first in the present invention.
【0010】本発明における有効成分化合物は、天然物
由来であるため、その毒性が低く、例えばこれを毎日2
50mg/kg、100日間という長期間に亘ってラッ
トに投与しても死亡例は認められず、体重変化も観察さ
れなかった。そのうえ、該有効成分化合物は、活性酸素
消去作用が強く且つ各種の剤型で使用できるので、飲食
品、医薬品、化粧品等において自由に使用することがで
きる。Since the active ingredient compound of the present invention is derived from a natural product, its toxicity is low.
No death was observed and no change in body weight was observed even when the rats were administered with 50 mg / kg for a long period of 100 days. Moreover, since the active ingredient compound has a strong active oxygen scavenging action and can be used in various dosage forms, it can be freely used in foods and drinks, pharmaceuticals, cosmetics and the like.
【0011】本有効成分化合物を飲食品以外の形態で使
用するには、経口投与、塗布、その他の非経口投与によ
り使用するが、例えば、経口投与のための製剤として
は、錠剤、丸剤、顆粒剤、軟・硬カプセル剤、散剤、細
粒剤、粉剤、乳濁剤、懸濁剤、シロップ剤、ペレット
剤、エリキシル等が挙られる。非経口投与のための製剤
としては、注射剤、点滴剤、輸液、軟膏、ローション、
トニック、スプレー、懸濁剤、油剤、乳剤、坐剤等が挙
られる。本発明の有効成分を製剤化するには、常法にし
たがえばよく、界面活性剤、賦形剤、着色料、着香料、
保存料、安定剤、緩衝剤、懸濁剤、等張剤その他常用さ
れる坐薬を適宜使用する。外用剤の場合も同様である。When the compound of the present active ingredient is used in a form other than food and drink, it is used by oral administration, coating, or other parenteral administration. For example, as a preparation for oral administration, tablets, pills, Granules, soft / hard capsules, powders, fine granules, powders, emulsions, suspensions, syrups, pellets, elixirs and the like can be mentioned. Formulations for parenteral administration include injections, drops, infusions, ointments, lotions,
Examples include tonics, sprays, suspensions, oils, emulsions and suppositories. To formulate the active ingredient of the present invention, a conventional method may be followed, including a surfactant, an excipient, a coloring agent, a flavoring agent,
Preservatives, stabilizers, buffers, suspensions, isotonic agents and other commonly used suppositories are used as appropriate. The same applies to external preparations.
【0012】本発明に係る抗酸化剤の投与量は、その種
類、治療ないし予防対象疾病の種類、投与方法、患者の
年令、患者の症状、処理時間等によって相違するが、静
脈投与の場合は成人1人当り1日に有効成分を0.01
〜2000mg/kg、筋肉投与の場合は同じく0.0
1〜3000mg/kg、経口投与の場合も同じく0.
5〜4000mg/kgの範囲内で投与するのが好まし
い。また、化粧料、皮膚外用剤として使用する場合は、
常法にしたがい適量を患部に塗布する。The dose of the antioxidant according to the present invention varies depending on the type, the type of disease to be treated or prevented, the administration method, the age of the patient, the symptoms of the patient, the treatment time, etc. Is 0.01 active ingredient per adult per day
~ 2000 mg / kg, 0.0 for intramuscular administration
1-3000 mg / kg, and the same for oral administration.
It is preferably administered within the range of 5-4000 mg / kg. When used as a cosmetic or external preparation for skin,
Apply an appropriate amount to the affected area according to a conventional method.
【0013】次に本発明の有効成分である加水分解型タ
ンニンの活性酸素消去の効果および脂質の過酸化を抑制
する効果を示す例を実施例として以下に示す。Next, examples showing the effect of hydrolyzable tannin as an active ingredient of the present invention on the elimination of active oxygen and the effect of suppressing lipid peroxidation will be shown below as examples.
【0014】[0014]
【実施例1】Example 1
【0015】1)方法 試験管に0.4mMキサンチンと0.24mMニトロブ
ルーテトラゾリウムの混合液1.0mlに、1,2,6
−トリ−O−ガロイル−β−D−グルコースおよび/ま
たは2,3−ジ−O−ガロイル−4,6−(O−4,
4’,5,5’,6,6’−ヘキサヒドロキシジフェノ
イル)−D−グルコースのジメチルスルホキシド水溶液
0.1mlを加えた試液を調製し、これにキサンチンオ
キシデース(0.049unit/ml)1.0mlを
加えた後、セ氏37度で20分間反応させる。反応後、
69mMドデシル硫酸ナトリウム2.0mlを加えて反
応を停止させ、十分に撹拌して波長560nmでの吸光
度を測定した。1) Method In a test tube, 1.0 ml of a mixed solution of 0.4 mM xanthine and 0.24 mM nitroblue tetrazolium was added to 1, 2, 6
-Tri-O-galloyl-β-D-glucose and / or 2,3-di-O-galloyl-4,6- (O-4,
4 ', 5,5', 6,6'-Hexahydroxydiphenoyl) -D-glucose was added to 0.1 ml of a dimethylsulfoxide aqueous solution to prepare a test solution, and xanthine oxidase (0.049 unit / ml) was prepared. After adding 1.0 ml, the mixture is reacted at 37 degrees Celsius for 20 minutes. After the reaction
The reaction was stopped by adding 2.0 ml of 69 mM sodium dodecyl sulfate, stirred sufficiently, and the absorbance at a wavelength of 560 nm was measured.
【0016】2)試験結果 同上の方法においてタンニンの代わりに牛の赤血球より
精製されたスーパーオキサイドディスミューテース(C
u,Zn−SOD)を添加して、その吸光度から検量線
を作成した。得られた検量線から1,2,6−トリ−O
−ガロイル−β−D−グルコース及び2,3−ジ−O−
ガロイル−4,6−(O−4,4’,5,5’,6,
6’−ヘキサヒドロキシジフェノイル)−D−グルコー
スの活性を算出した。下記の表1にこれらタンニンのス
ーパーオキサイドディスミューテース(SOD)様活性
を示す。2) Test results Superoxide dismutase (C) purified from bovine erythrocytes instead of tannin in the same method as above
u, Zn-SOD) was added and a calibration curve was prepared from the absorbance. From the calibration curve obtained, 1,2,6-tri-O
-Galloyl-β-D-glucose and 2,3-di-O-
Galloyl-4,6- (O-4,4 ', 5,5', 6,6
The activity of 6'-hexahydroxydiphenoyl) -D-glucose was calculated. Table 1 below shows the superoxide dismutase (SOD) -like activity of these tannins.
【0017】[0017]
【表1】 [Table 1]
【0018】以上の結果より明らかなように、これらの
加水分解型タンニンはスーパーオキサイドアニオンラジ
カルに対する消去作用を持ち、低分子物質として実用に
供されるものである。As is clear from the above results, these hydrolyzable tannins have a scavenging action on superoxide anion radicals and are put to practical use as low molecular weight substances.
【0019】[0019]
【実施例2】Example 2
【0020】1)方法 試験管に兎の赤血球ゴースト膜(2.5mg蛋白/m
l)0.9mlと1,2,6−トリ−O−ガロイル−β
−D−グルコース及び2,3−ジ−O−ガロイル−4,
6−(O−4,4’,5,5’,6,6’−ヘキサヒド
ロキシジフェノイル)−D−グルコースのジメチルスル
ホキシド溶液0.1mlを入れ、ジメチルスルホキシド
に溶解したtert−ブチルハイドロパーオキサイド
(10mg/ml)9μlを添加して、反応を開始させ
た。反応はセ氏37度で30分間行ない、2Mトリクロ
ロ酢酸1.0mlを加えて反応を止めた。これに0.6
7%チオバルビツール酸2.0mlを添加して沸騰水浴
中で15分間反応させ、この反応により生じるマロンジ
アルデヒドをはじめとするチオバルビツール酸反応陽性
物質の量を波長535nmでの吸光度測定により求め
た。この値をもとに脂質過酸化を50%抑制する濃度を
求め、市販の合成抗酸化剤であるブチルヒドロキシアニ
ソールに対する抗酸化活性を算出した。1) Method A rabbit red blood cell ghost membrane (2.5 mg protein / m 2) was placed in a test tube.
l) 0.9 ml and 1,2,6-tri-O-galloyl-β
-D-glucose and 2,3-di-O-galloyl-4,
6- (O-4,4 ′, 5,5 ′, 6,6′-hexahydroxydiphenoyl) -D-glucose in 0.1 ml of dimethyl sulfoxide was added, and tert-butyl hydroper was dissolved in dimethyl sulfoxide. The reaction was initiated by the addition of 9 μl of oxide (10 mg / ml). The reaction was carried out at 37 degrees Celsius for 30 minutes, and the reaction was stopped by adding 1.0 ml of 2M trichloroacetic acid. 0.6 for this
By adding 2.0 ml of 7% thiobarbituric acid and reacting for 15 minutes in a boiling water bath, the amount of thiobarbituric acid reaction positive substances such as malondialdehyde produced by this reaction was measured by absorbance at a wavelength of 535 nm. I asked. Based on this value, the concentration at which lipid peroxidation was suppressed by 50% was determined, and the antioxidant activity against butylhydroxyanisole, which is a commercially available synthetic antioxidant, was calculated.
【0021】2)試験結果 兎赤血球膜脂質の過酸化を50%抑制する濃度を指標と
して、1,2,6−トリ−O−ガロイル−β−D−グル
コース及び2,3−ジ−O−ガロイル−4,6−(O−
4,4’,5,5’,6,6’−ヘキサヒドロキシジフ
ェノイル)−D−グルコースの抗酸化活性を下記の表2
に示す。2) Test Results 1,2,6-tri-O-galloyl-β-D-glucose and 2,3-di-O-, using the concentration at which the peroxidation of rabbit erythrocyte membrane lipids is suppressed by 50% as an index. Galloyl-4,6- (O-
The antioxidant activity of 4,4 ′, 5,5 ′, 6,6′-hexahydroxydiphenoyl) -D-glucose is shown in Table 2 below.
Shown in.
【0022】[0022]
【表2】 [Table 2]
【0023】以上の結果より明らかなように、加水分解
型タンニンの抗酸化活性は市販の合成抗酸化剤であるブ
チルヒドロキシアニソールの活性に比較して、モル比で
3倍程度強力である。As is clear from the above results, the antioxidative activity of hydrolyzed tannin is about 3 times as potent as the molar activity of butylhydroxyanisole which is a commercially available synthetic antioxidant.
【0024】[0024]
【発明の効果】本発明の有効成分である加水分解型タン
ニンは生体内の代謝により発生し、炎症、発癌、放射能
障害、免疫、白内障、動脈硬化、心筋虚血、老化、痙
攣、脳卒中、糖尿病などの諸疾患の原因になる活性酸
素、特にスーパーオキサイドアニオンラジカルを直接消
去する有用な抗酸化剤であり、食品、医薬品、化粧品の
素材などとして広く産業上利用されるものである。The hydrolyzable tannin, which is the active ingredient of the present invention, is generated by metabolism in the body and causes inflammation, carcinogenesis, radioactivity disorder, immunity, cataract, arteriosclerosis, myocardial ischemia, aging, convulsion, stroke, It is a useful antioxidant for directly scavenging active oxygen, especially superoxide anion radicals, which causes various diseases such as diabetes, and is widely industrially used as a material for foods, pharmaceuticals, cosmetics and the like.
Claims (2)
とを特徴とする活性酸素消去作用を有する抗酸化剤。1. An antioxidant having an active oxygen scavenging action, which comprises hydrolyzable tannin as an active ingredient.
リ−O−ガロイル−β−D−グルコースおよび/または
2,3−ジ−O−ガロイル−4,6−(O−4,4’,
5,5’,6,6’−ヘキサヒドロキシジフェノイル)
−D−グルコースであることを特徴とする請求項1に記
載の活性酸素消去作用を有する抗酸化剤。2. The hydrolyzable tannin is 1,2,6-tri-O-galloyl-β-D-glucose and / or 2,3-di-O-galloyl-4,6- (O-4, 4 ',
5,5 ', 6,6'-hexahydroxydiphenoyl)
The antioxidant having an active oxygen scavenging action according to claim 1, which is -D-glucose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2160692A JPH05186769A (en) | 1992-01-13 | 1992-01-13 | Antioxidant which eliminates active oxygen |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2160692A JPH05186769A (en) | 1992-01-13 | 1992-01-13 | Antioxidant which eliminates active oxygen |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH05186769A true JPH05186769A (en) | 1993-07-27 |
Family
ID=12059697
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2160692A Pending JPH05186769A (en) | 1992-01-13 | 1992-01-13 | Antioxidant which eliminates active oxygen |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH05186769A (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0727218A3 (en) * | 1995-02-10 | 1997-01-15 | Suntory Ltd | Anti-allergic composition containing god-type ellagitannin as active ingredient |
EP0727217A3 (en) * | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical composition containing god-type ellagitannin as active ingredient |
JPH0959151A (en) * | 1995-08-24 | 1997-03-04 | Kao Corp | Nf-kappa b activation suppressing agent |
JP2008156340A (en) * | 1998-02-06 | 2008-07-10 | Nagaoka Koryo Kk | Active oxygen eliminating agent, skin conditioning agent and antitarnishing agent |
US8453487B2 (en) | 2008-10-10 | 2013-06-04 | Tosoh Smd, Inc. | Circular groove pressing mechanism and method for sputtering target manufacturing |
KR101440677B1 (en) * | 2012-07-11 | 2014-09-17 | 중앙대학교 산학협력단 | Novel Hydrolysable Tannis Isolated from the Leaves of Cleyera japonica Thunberg and Anti-Oxidative Use Thereof |
-
1992
- 1992-01-13 JP JP2160692A patent/JPH05186769A/en active Pending
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0727218A3 (en) * | 1995-02-10 | 1997-01-15 | Suntory Ltd | Anti-allergic composition containing god-type ellagitannin as active ingredient |
EP0727217A3 (en) * | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical composition containing god-type ellagitannin as active ingredient |
JPH0959151A (en) * | 1995-08-24 | 1997-03-04 | Kao Corp | Nf-kappa b activation suppressing agent |
JP2008156340A (en) * | 1998-02-06 | 2008-07-10 | Nagaoka Koryo Kk | Active oxygen eliminating agent, skin conditioning agent and antitarnishing agent |
US8453487B2 (en) | 2008-10-10 | 2013-06-04 | Tosoh Smd, Inc. | Circular groove pressing mechanism and method for sputtering target manufacturing |
KR101440677B1 (en) * | 2012-07-11 | 2014-09-17 | 중앙대학교 산학협력단 | Novel Hydrolysable Tannis Isolated from the Leaves of Cleyera japonica Thunberg and Anti-Oxidative Use Thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69333775T2 (en) | SYNTHETIC CATALYTIC FREE RADICAL RECIPIENTS, USED AS ANTIOXIDANTS FOR THE PREVENTION AND THERAPY OF DISEASES | |
JP3014109B2 (en) | Synthetic GTF chromium material and method | |
TWI291350B (en) | Pharmaceutical composition for ophthalmic use | |
EP3548058B1 (en) | Compositions comprising peptide wkdeagkplvk | |
KR20000052687A (en) | Magnesium (-)Hydroxycitrate, Method of Preparation, Applications, and Compositions in Particular Pharmaceutical Containing Same | |
TW201219370A (en) | Agent for regulating the formation of nitrogen monoxide | |
JPH05186769A (en) | Antioxidant which eliminates active oxygen | |
TW461814B (en) | Eliminating agent for activated oxygen and free radicals | |
JP5524126B2 (en) | Reactive chlorine compounds, derivatives thereof, anions and salts, production methods thereof and uses thereof | |
KR20160021734A (en) | Antioxidative composition comprising extract of red tea stem | |
CN112043701A (en) | Medical application of long-chain quaternary ammonium salt compound | |
KR20160035641A (en) | phloretine sulfonate and compositions for improving skin conditions comprising phloretine sulfonate | |
CN113069486B (en) | Hypericum perforatum extract for inhibiting coronavirus 3CL proteolytic enzyme and medical application thereof | |
JP2004189737A (en) | Antifungal agent | |
CN110709087A (en) | Skin problem inhibitor and composition for inhibiting skin problems | |
JP2024533530A (en) | Anti-inflammatory composition containing complex ginsenoside composition | |
JPH0383548A (en) | Super oxide eliminating agent, food and drink and cosmetic | |
JP7542055B2 (en) | Inhibitor of degradation of denatured elastin, agent for maintaining normal elastin fibers, agent for inhibiting formation of elastin-elafin complex, and composition containing the same | |
JP2007326796A (en) | Bleaching agent containing gold colloid and thyrosinase inhibitor | |
JPH0859485A (en) | Maillard reaction inhibitor consisting mainly of 3-oxygermylpropionic acid compound | |
JP2003176230A (en) | Collagen production promoter, elastase inhibitor, collagenase inhibitor and skin cosmetic and beautifying foods or beverage | |
EP2666460A1 (en) | Skin-whitening agent containing 3-hydroxy-2-pyrone | |
JP2002543209A (en) | Antioxidant vitamin B6 analog | |
US20230312643A1 (en) | Peptide derivative with collagenase inhibitory activity, and use thereof | |
KR0184226B1 (en) | Functional drinks containing melatonin |